BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 27,802 shares of BeOne Medicines stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $253.38, for a total value of $7,044,470.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
John Oyler also recently made the following trade(s):
- On Monday, June 23rd, John Oyler sold 3,174 shares of BeOne Medicines stock. The shares were sold at an average price of $261.61, for a total value of $830,350.14.
- On Tuesday, June 17th, John Oyler sold 1,460 shares of BeOne Medicines stock. The shares were sold at an average price of $256.49, for a total value of $374,475.40.
- On Monday, June 16th, John Oyler sold 3,680 shares of BeOne Medicines stock. The shares were sold at an average price of $266.05, for a total value of $979,064.00.
- On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The shares were sold at an average price of $252.77, for a total value of $1,295,951.79.
BeOne Medicines Stock Down 1.2%
Shares of BeOne Medicines stock traded down $3.09 on Friday, hitting $250.30. The stock had a trading volume of 371,565 shares, compared to its average volume of 302,202. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $146.21 and a twelve month high of $287.88. The company has a 50 day moving average price of $247.19. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $27.43 billion, a PE ratio of -67.28 and a beta of 0.28.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. As a group, equities analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the company. TD Securities reissued a "buy" rating and set a $334.00 price target on shares of BeOne Medicines in a research report on Thursday, April 24th. Morgan Stanley boosted their price target on BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research report on Friday, June 27th. Guggenheim boosted their price target on BeOne Medicines from $348.00 to $350.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. boosted their price target on BeOne Medicines from $317.00 to $321.00 and gave the stock an "overweight" rating in a research report on Friday, June 27th. Finally, Wall Street Zen downgraded BeOne Medicines from a "buy" rating to a "hold" rating in a research report on Saturday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, BeOne Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $320.67.
Check Out Our Latest Report on ONC
Institutional Investors Weigh In On BeOne Medicines
A number of large investors have recently added to or reduced their stakes in ONC. Farther Finance Advisors LLC acquired a new stake in BeOne Medicines during the second quarter worth approximately $39,000. Parallel Advisors LLC acquired a new stake in BeOne Medicines during the second quarter worth approximately $59,000. Finally, Aaron Wealth Advisors LLC acquired a new stake in BeOne Medicines during the second quarter worth approximately $200,000. Institutional investors and hedge funds own 48.55% of the company's stock.
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
See Also
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
